Psoriasis (PsO) is a chronic inflammatory skin disease with both local and systemic components. PsO-associated arthritis, known as psoriatic arthritis (PsA 
| INTRODUC TI ON
Psoriasis (PsO) is a chronic inflammatory skin disease that affects up to 3.8% of the population. 1 Cell-mediated immunity, excessive growth and aberrant differentiation of keratinocytes, and increased dermal vascularity all play important roles in the pathomechanisms of PsO. 2 Approximately 13%-25% of PsO patients develop psoriatic arthritis (PsA), characterized by peripheral arthritis, axial spondylitis and enthesitis. 3, 4 According to the Classification of Psoriatic Arthritis (CASPAR) criteria, 5 current or past presence of psoriasis of the skin, or a positive family history, represents a major criterion for the diagnosis of PsA. Interaction among genetic, environmental and immune factors leads to psoriatic skin and joint manifestations. 6, 7 Both the skin and synovium of patients with PsA produce increased concentrations of proinflammatory cytokines. Various factors, including human leucocyte antigens (HLA), the interleukin (IL)-23/IL-17 axis and tumour necrosis factor-α (TNF-α), are related to PsO and PsA and support the hypothesis that PsO and PsA are different manifestations of a single disease. 8, 9 On the one hand, revealing differences between PsO and PsA will provide insight into their respective pathophysiologies. On the other hand, identification of novel targets for treatment of both PsO and PsA is important for simpler and more patient-friendly treatment
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TIAN eT Al regimens. These targets will most likely represent 'common checkpoints' of inflammation, including key components or transduction cascades of the signalling pathways involved, rather than 'common denominators' such as cytokines. 10, 11 For example, small molecules that inhibit enzymes such as Janus kinases or phosphodiesterase 4
have proved effective in treating PsO and PsA. 12, 13 In this context, the Wnt5a signalling pathway is an attractive target for the treatment of PsO as well as PsA.
| WNT5A AND PSO

| Wnt5a signalling pathway
Wnt signalling, which plays important roles in regulating cell proliferation, differentiation, polarity, migration and inflammation, [14] [15] [16] [17] [18] is classified into β-catenin-dependent canonical and β-catenin-inde- The key molecules and cascades in the non-canonical pathway have been previously summarized. 19, 20 
| Wnt5a is differentially expressed in psoriatic skin
Reischl et al 23 found that Wnt5a expression was fourfold higher than normal in skin lesions from patients with plaque-type psoriasis.
Another study with more subjects showed that Wnt5a transcripts were up-regulated fivefold in skin lesions and that FZD2 and FZD5
F I G U R E 1 Model of the role and proposed mechanism of Wnt5a in psoriasis. Activation of Wnt5a signaling and its downstream effectors by local or systemic pathogens stimulate keratinocyte proliferation and secretion of inflammatory cytokines, which further regulate Wnt5a expression and promote keratinocyte proliferation and activation through Wnt5a-mediated signalling pathways. This cross-talk forms a signalling loop that promotes the persistence of PsO inflammation and disease progression expression was also increased, while mRNA levels of WIF1 (a Wnt antagonist) were down-regulated >10-fold. 24 We previously demon- 
| PROP OS ED MECHANIS M OF WNT5A INVOLVEMENT IN PSO
| Wnt5a and keratinocytes
Interplay between the immune system and the epithelium is the pathological trigger of PsO. The activated adaptive and innate im- and IL-23. IL-1α, TNF-α, transforming growth factor-α and interferon-γ stimulated keratinocytes to produce higher levels of Wnt5a, which, in turn, repressed both Notch1 and HES1. 32 
| Wnt5a and inflammation
| Interaction with inflammatory cytokines
Immune cell infiltration is one of the main characteristics of psoriatic 
| T cells
Wnt5a is a critical mediator of migration and CXC chemokine li- 43 Holtzhausen et al 
| Macrophages and neutrophils
Macrophage recruitment is another characteristic of inflammation, including in PsO. An in vitro study focusing on Wnt5a interaction with macrophages in castration-resistant prostate cancer (CRPC) indicated that Wnt5a may be a crucial regulator that induces CRPC in the bone niche by recruiting and regulating macrophages. 46 Another in vitro study confirmed that Wnt5a induces macrophage chemotaxis and activation. 47 Recombinant Wnt5a-induced cytokine secretion by macrophages from C57BL/6 mice was dependent on TLR4 and was repressed by polymyxin B. 48 Moreover, Wnt5a is upregulated in macrophages stimulated with endotoxin (LPS), which induces the expression of IL-1β, IL-6, IL-8 and macrophage inflammatory protein-1β. 22 In fact, macrophage-derived Wnt5a is an important regulator of macrophage immune function, pro-inflammatory cytokine release, angiogenesis and lymphangiogenesis. 49 Human neutrophils express a number of Wnt5a receptors, including FZD2, 5 and 8. Wnt5a stimulation of human neutrophils leads to chemotactic migration and the secretion of CXCL8 and CCL2.
Neutrophil chemotaxis induced by supernatant collected from LPSstimulated macrophages was markedly inhibited by an antagonist of Wnt5a, which indicates that Wnt5a may contribute to neutrophil recruitment, thereby regulating the inflammation response. 
| WNT5A AND PSA
PsA targets the spine, peripheral joints and the entheses. 55 The aetiology of PsA is unclear, but is thought to be an interplay of genetic, immunological and environmental factors that promote pathological bone remodelling and joint damage. 
| CON CLUS IONS
Based on the findings presented in this review, we propose that 
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